Authors
Latest:
The Fruits of Comparative EffectivenessNew CER tools grant payers the evidence they need to control drug costs
Latest:
Coupon-Program Pivot: Meeting New Legal, Operational HurdlesPharma manufacturers may need to upgrade their coupon programs to accommodate for the emergence of copay accumulators and related benefit mechanisms.
Latest:
Making the Most of Management ConsultingIntense regulatory demands, cost pressure, and the need to be ever more efficient has led to an upturn in the use of management consultants in the pharma & biotech sector, writes B.J. Richards.
Latest:
Raising the Stakes On Value-Based PricingThe importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .
Latest:
Pricing for Rare Disease and Curative Therapies: What’s Fair?There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.
Latest:
Data Unleashed: Cooperation Among CompetitorsCharting two years of collaborative progress in clinical trial data sharing.
Latest:
Closing the Gaps in Drug Chain of CustodyLimitations of the Drug Supply Chain Security Act for pharma-and three strategies to fix them.
Latest:
Who Will Win the Race to Treat NASH?The liver disease non-alcoholic steatohepatitis (NASH) has become a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. The race is now to develop the first effective pharmacotherapy to treat it.
Latest:
Pharma’s Big Push for ValueAn “how to” primer for life sciences companies on applying end-to-end evidence strategies in demonstrating product value.
Latest:
Making the Most Out of Your Real EstateAs companies look to raise capital, selling and then leasing back real estate is a tempting option and one that other industries are utilizing, writes Karen Williamson.
Latest:
Registries and the Future of MedicinePayers, providers, patients and pharma companies all want to understand the value of specific treatments – and patient registries can help them do that.
Latest:
Real-time Data Tracking in the Clinical Trial Supply ChainGood Distribution Practice means that ‘track and trace’ is becoming indispensable for drug product integrity. Interactive Response Technologies may offer a potential solution.
Latest:
Investing in Patient-Centric Capabilities Requires a Clear StrategyFor those willing to invest in the right capabilities, offering patient services can give pharma companies a tremendous opportunity.
Latest:
Mining Cancer Kryptonite from Historic Clinical Trial DataClinical trial data from completed trials are now beginning to be shared through a variety of channels. While skeptics remain, evidence is growing that this data can lead to practice-changing behavior in patient care.
Latest:
A Digital Prescription for the Pharma IndustryHow companies can better integrate valuable data across business functions to meet rising value-chain demands.
Latest:
A Digital Prescription for the Pharma IndustryHow companies can better integrate valuable data across business functions to meet rising value-chain demands.
Latest:
A Digital Prescription for the Pharma IndustryHow companies can better integrate valuable data across business functions to meet rising value-chain demands.
Latest:
A Digital Prescription for the Pharma IndustryHow companies can better integrate valuable data across business functions to meet rising value-chain demands.
Latest:
Redefining Evidence: A Paradigm Shift to Unlock Access for Innovative TherapiesWhy pharma and all stakeholders in the healthcare ecosystem should undertake a fundamental shift in how evidence to support new treatments is generated and assessed.
